Afamitresgene autoleucel (Afami-cel)
Tecelra · MAGE-A4 TCR-T cell therapy
First TCR-T cell therapy for a solid tumor; CRS-associated hemodynamic AKI.
Rytelo · IMET
Telomerase inhibitor · approved 2024 · 5 citations
Describes how this page is sourced, not how dangerous the drug is. Thinly sourced means fewer of the sourcing signals are met — not that the agent is kidney-safe. A rule-based summary, not a formal certainty appraisal.
A first-in-class telomerase inhibitor for low-risk MDS — kidney concern is mainly tumor-lysis/cytopenia, not direct toxicity.
Atlas fields gathered in one place, each linked to the section with its full text and sources. Educational, not medical advice.
Signature lesion
No established direct nephrotoxicity. In IMerge the dominant toxicities were cytopenias (thrombocytopenia, neutropenia); renal injury was not a defining adverse event. Tumor-lysis-type metabolic risk is theoretical and most relevant with high disease burden, not a quantified rate in lower-risk MDS.Source: Platzbecker et al., Lancet 2023
Any tumor-lysis-type risk arises early after initiation; otherwise no defined renal onset.
Distilled from: “Any tumor-lysis-type risk would be early after initiation; otherwise no defined renal onset.”
This agent's kidney lesions ordered by prominence — the #1 signature lesion first, then secondary and rare patterns. Cited incidence is shown where a citable figure exists; otherwise the tier stands qualitatively.
Renal hypoperfusion from capillary leak and cytokine storm — IL-2 and CAR-T cytokine release syndrome.
Renal electrolyte derangement — magnesium/potassium/calcium wasting (cisplatin, anti-EGFR antibodies) or retention (FGFR-inhibitor hyperphosphatemia, tumor-lysis hyperkalemia/hyperphosphatemia).
13-mer lipid-conjugated oligonucleotide that binds the RNA template (hTR) of telomerase via Watson-Crick base pairing, competitively inhibiting telomerase enzymatic activity and shortening telomeres in malignant clones. Approved for transfusion-dependent anemia in lower-risk myelodysplastic syndromes (MDS) refractory to or ineligible for erythropoiesis-stimulating agents.
Vasculature / Endothelium
Glomerular & peritubular capillaries
5 primary references — trials, cohorts, mechanism, and reviews. Citation metadata via PubMed / NLM.
Primary (non–case-report) references per year — a proxy for how actively the agent's renal literature is accruing. Recent years are highlighted. Reflects curation depth, not a systematic bibliometric count.
Everything below is FAERS — adverse events someone chose to report, about 186 of them for this agent. Nobody counts the patients who were fine, so none of these numbers is an incidence, a risk, or a rate: they describe what gets reported, shaped by a drug's fame, its indication, and who was watching. How these numbers work.
Reported with a death outcome
11 of 186 reports
Reported with hospitalization
36 of 186 reports
Reports per year
Reports received per year, 2015–2026 · most recent year is partial.
Bars rank systems by summed reaction-term mentions (a report counts once per term it names) — an ordinal “more vs less reported” cue, not a tally of distinct reports. Renal & urinary first. As of 2026-11-15.
Each recommendation below is this atlas's faithful summary of the source, not a quotation from it — follow the PubMed link for the wording the society published. Summaries may be superseded; consult the current full text and individualize to the patient.
General onco-nephrology references
Where Imetelstat sits in nephrotoxicity space — each dot is an anti-cancer agent, positioned so neighbors share a kidney-injury phenotype. Its 6 closest are filled and lead to a numbered marker, matching the numbered cards below.
Tecelra · MAGE-A4 TCR-T cell therapy
First TCR-T cell therapy for a solid tumor; CRS-associated hemodynamic AKI.
Komzifti · Menin inhibitor
2025 NPM1-mutated AML menin inhibitor; differentiation syndrome and tumor lysis.
Ziihera · HER2 bispecific antibody
2024 biliary-tract HER2 bispecific; renal data emerging.
Bizengri · HER2×HER3 bispecific antibody
2024 NRG1-fusion bispecific; mostly grade 1-2 AEs — at most diarrhea-related prerenal risk, no CRS/TLS mechanism.
Gomekli · MEK inhibitor
2025 NF1 MEK inhibitor; creatinine rise and edema.
Vanflyta · FLT3 inhibitor
2023 AML FLT3 inhibitor; tumor lysis and QT.
Nearest agents by kidney-injury phenotype (shared injuries, nephron target, severity, class) — a similarity approximation, not a claim of shared drug identity or mechanism.